The reference standard for fosfomycin antimicrobial susceptibility testing (AST) is agar dilution, but it is laborious and is not routinely used in diagnostic microbiology. In this study, we evaluated the performance of a ready-to-use commercially available agar dilution kit for fosfomycin AST (Liofilchem Diagnostics). We compared this kit with the reference standard agar dilution, performed according to the Clinical & Laboratory Standards Institute (CLSI) in 229 clinical isolates. The isolates were selected to represent both Gram-positive and Gram-negative microorganisms, with various MIC values. It consisted of 43 enterococci (E. faecalis = 16, E. faecium = 27), 13 methicillin-resistant S. aureus (MRSA), 118 Enterobacterales (Escherichia coli = 94, Klebsiella pneumoniae = 20, and Enterobacter cloacae complex = 4), 55 Pseudomonas aeruginosa, and three ATCC isolates. Using CLSI breakpoints for enterococci for oral treatment of urinary tract infections, European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints for intravenous dosing for Enterobacterales and Staphylococci, and epidemiological cutoff value for P. aeruginosa, the essential agreement was 87.5%, and 99.6% after discrepancy resolution. There was no very major error, and 1.9% major error before, and 0.9% major error after resolution of discrepancies. The commercial test showed 100% reproducibility. In conclusion, in comparison to the reference standard, the ready-to-use commercially available agar dilution kit for fosfomycin AST showed excellent performance. Fosfomycin is increasingly needed to treat infection due to multidrug resistant microorganisms. Yet, the antimicrobial susceptibility test (AST) of fosfomycin is fraught with difficulties or often laborious to perform. An easy-to-use AST method for fosfomycin is thus needed. In this study, we showed that the ready-to-use commercially available agar dilution kit, in comparison to the reference standard, showed excellent performance.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045359 | PMC |
http://dx.doi.org/10.1128/spectrum.02504-21 | DOI Listing |
J Clin Microbiol
January 2025
Department of Pathology, Harbor-UCLA Medical Center, Torrance, California, USA.
The complex (BCC) is a group of Gram-negative bacteria that cause opportunistic infections, most notably in people with cystic fibrosis (CF), and have been associated with outbreaks caused by contaminated medical products. Antimicrobial susceptibility testing (AST) is often used to guide treatment for BCC infections, perhaps most importantly in people with CF who are being considered for lung transplant. However, recent studies have highlighted problems with AST methods.
View Article and Find Full Text PDFRSC Adv
January 2025
Department of Physics and Chemistry, Faculty of Education, Alexandria University Egypt.
A novel series of azo dyes was successfully synthesized by combining amino benzoic acid and amino phenol on the same molecular framework azo linkage. The structural elucidation of these dyes was carried out using various spectroscopic techniques, including UV-vis, FT-IR, NMR spectroscopy, and HRMS. Surprisingly, the aromatic proton in some dyes exhibited exchangeability in DO, prompting a 2D NMR analysis to confirm this phenomenon.
View Article and Find Full Text PDFAnn Clin Microbiol Antimicrob
January 2025
Division of Infectious Diseases, Department of Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei, 100, Taiwan.
Background: Nemonoxacin is a new quinolone with an antibacterial efficacy against methicillin-resistant Staphylococcus aureus (MRSA). Certain sequence types (STs) have been emerging in Taiwan, including fluoroquinolone-resistant ST8/USA300. It's an urgent need to determine nemonoxacin susceptibility against ST8/USA300 and other emerging lineages, if any.
View Article and Find Full Text PDFBMC Microbiol
January 2025
Department of Microbiology and Immunology, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo, 11562, Egypt.
Background: One of the main issues facing public health with microbial infections is antibiotic resistance. Nanoparticles (NPs) are among the best alternatives to overcome this issue. Silver nanoparticle (AgNPs) preparations are widely applied to treat multidrug-resistant pathogens.
View Article and Find Full Text PDFPak J Pharm Sci
January 2025
Department of Medical Microbiology, Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.
Antimicrobial peptides (AMPs) may mitigate the danger of increasing antimicrobial resistance. We aimed to determine the activities of catestatin, temporin A, nisin and cecropin A against Bacteroides fragilis ATCC 25285, Prevotella melaninogenica ATCC 25845, Cutibacterium acnes ATCC 6919, Peptostreptococcus anaerobius ATCC 27337 and Peptostreptococcus stomatis DSM 17678. strains.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!